The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer

Theresa E. Hickey,Luke A. Selth,Kee Ming Chia,Geraldine Laven-Law,Heloisa H. Milioli,Daniel Roden,Shalini Jindal,Mun Hui,Jessica Finlay-Schultz,Esmaeil Ebrahimie,Stephen N. Birrell,Suzan Stelloo,Richard Iggo,Sarah Alexandrou,C. Elizabeth Caldon,Tarek M. Abdel-Fatah,Ian O. Ellis,Wilbert Zwart,Carlo Palmieri,Carol A. Sartorius,Alex Swarbrick,Elgene Lim,Jason S. Carroll,Wayne D. Tilley

DOI: https://doi.org/10.1038/s41591-020-01168-7

IF: 82.9

2021-01-18

Nature Medicine

Abstract:The role of the androgen receptor (AR) in estrogen receptor (ER)-α-positive breast cancer is controversial, constraining implementation of AR-directed therapies. Using a diverse, clinically relevant panel of cell-line and patient-derived models, we demonstrate that AR activation, not suppression, exerts potent antitumor activity in multiple disease contexts, including resistance to standard-of-care ER and CDK4/6 inhibitors. Notably, AR agonists combined with standard-of-care agents enhanced therapeutic responses. Mechanistically, agonist activation of AR altered the genomic distribution of ER and essential co-activators (p300, SRC-3), resulting in repression of ER-regulated cell cycle genes and upregulation of AR target genes, including known tumor suppressors. A gene signature of AR activity positively predicted disease survival in multiple clinical ER-positive breast cancer cohorts. These findings provide unambiguous evidence that AR has a tumor suppressor role in ER-positive breast cancer and support AR agonism as the optimal AR-directed treatment strategy, revealing a rational therapeutic opportunity.

biochemistry & molecular biology,cell biology,medicine, research & experimental